Dataset from A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer

This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in
adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and
trastuzumab and have undergone surgical treatment of human epidermal growth factor receptor 2
(HER2)-positive early breast cancer. The study will consist of two adjuvant treatment
periods: a treatment cross-over period and a treatment continuation period. It will evaluate
participant-reported preference for a subcutaneously administered fixed-dose combination
formulation (FDC SC) of pertuzumab and trastuzumab compared with intravenously (IV)
administered pertuzumab and trastuzumab formulations. The study will also evaluate
participant-reported satisfaction with pertuzumab and trastuzumab FDC SC and health-related
quality of life outcomes; healthcare professionals' perceptions of time/resource use and
convenience of pertuzumab and trastuzumab FDC SC compared with pertuzumab and trastuzumab IV
formulations; as well as the safety and efficacy of each study regimen.